Telix Pharmaceuticals Limited Stock Total Asset
| TLPPF Stock | USD 15.50 0.50 3.33% |
Telix Pharmaceuticals Limited fundamentals help investors to digest information that contributes to Telix Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Telix Pink Sheet. The fundamental analysis module provides a way to measure Telix Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Telix Pharmaceuticals pink sheet.
Telix |
Telix Pharmaceuticals Limited Company Total Asset Analysis
Telix Pharmaceuticals' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Telix Pharmaceuticals Total Asset | 109.81 M |
Most of Telix Pharmaceuticals' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Telix Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Telix Pharmaceuticals Limited has a Total Asset of 109.81 M. This is 98.54% lower than that of the Healthcare sector and 94.44% lower than that of the Biotechnology industry. The total asset for all United States stocks is 99.63% higher than that of the company.
Telix Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telix Pharmaceuticals' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Telix Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Telix Pharmaceuticals by comparing valuation metrics of similar companies.Telix Pharmaceuticals is currently under evaluation in total asset category among its peers.
Telix Fundamentals
| Return On Equity | -1.55 | |||
| Return On Asset | -0.41 | |||
| Operating Margin | (3.95) % | |||
| Current Valuation | 1.39 B | |||
| Shares Outstanding | 317.02 M | |||
| Shares Owned By Insiders | 27.60 % | |||
| Shares Owned By Institutions | 13.59 % | |||
| Price To Book | 21.16 X | |||
| Price To Sales | 52.21 X | |||
| Revenue | 4.9 M | |||
| Gross Profit | 5.05 M | |||
| EBITDA | (70.07 M) | |||
| Net Income | (80.51 M) | |||
| Cash And Equivalents | 122.61 M | |||
| Cash Per Share | 0.39 X | |||
| Total Debt | 2.57 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 3.21 X | |||
| Book Value Per Share | 0.34 X | |||
| Cash Flow From Operations | (59.33 M) | |||
| Earnings Per Share | (0.20) X | |||
| Number Of Employees | 11 | |||
| Beta | 2.31 | |||
| Market Capitalization | 1.44 B | |||
| Total Asset | 109.81 M | |||
| Net Asset | 109.81 M |
About Telix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telix Pharmaceuticals Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telix Pharmaceuticals Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Telix Pink Sheet
When determining whether Telix Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telix Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telix Pharmaceuticals Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telix Pharmaceuticals Limited Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.